Vasoactive agent intraocular implant
First Claim
Patent Images
1. An intraocular implant for treating an ocular condition, the implant comprising:
- (a) a vasoactive compound, and;
(b) a carrier associated with the vasoactive compound, thereby forming an intraocular implant suitable for treating an ocular condition.
1 Assignment
0 Petitions
Accused Products
Abstract
Intraocular implants comprising a vasoactive compound and a polymer useful for treating an ocular condition. The vasoactive compound can be a vasodilator. The polymer can be a biodegradable polymer, and the ocular condition can be glaucoma.
-
Citations
32 Claims
-
1. An intraocular implant for treating an ocular condition, the implant comprising:
-
(a) a vasoactive compound, and;
(b) a carrier associated with the vasoactive compound, thereby forming an intraocular implant suitable for treating an ocular condition. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
-
16. an intraocular implant for treating an ocular condition, the implant comprising:
-
(a) a vasodilator compound, and;
(b) a biodegradable polymer associated with the vasoactive compound, thereby forming an intraocular implant suitable for treating an ocular condition, wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator compound over a period of up to about forty days. - View Dependent Claims (17, 18, 19, 29)
-
- 20. A method of making a biodegradable intravitreal implant, the method comprising the step of extruding a mixture of a vasodilator compound, and a biodegradable polymer, thereby making forming an intravitreal implant suitable for treating an ocular condition, wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator compound over a period of up to about forty days.
- 22. A method of improving or maintaining vision of an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a therapeutic agent which is a vasodilator wherein the implant degrades at a rate effective to sustain release of an amount of the therapeutic agent from the implant effective to improve or maintain vision in the eye of the patient.
-
30. A method for treating glaucoma by intravitreal administration of a sustained release drug delivery system comprising a biodegradable polymer and a therapeutically effective amount of a vasoactive agent associated with the polymer.
-
31. A method for improving vision, the method comprising the step of intraocular placement of an intraocular implant comprising a vasoactive compound and a carrier associated with the vasoactive compound.
-
32. A method to preventing vision loss, the method comprising the step of intraocular placement of an intraocular implant comprising a vasoactive compound and a carrier associated with the vasoactive compound.
Specification